НовостиBenzingaGuggenheim Maintains Buy on Rapport Therapeutics, Lowers Price Target to $66 Guggenheim Maintains Buy on Rapport Therapeutics, Lowers Price Target to $66 Benzinga 2026.11.05 16:07 (GMT+0) Открыть на Benzinga Другие новости